

**IN THE CLAIMS:**

1. A method for treating a neoplasm comprising cells, comprising:  
administering to said neoplasm an amount of a mutant human herpes simplex virus  
5 which is oncolytic to cells in said neoplasm, wherein said virus does not produce a  
functionally active wild-type glycoprotein C polypeptide.

2. A method of claim 1, wherein said virus comprises a deletion in the UL44 gene  
which codes for glycoprotein C.

3. A method of claim 1, wherein said virus comprises a deletion of amino acids 33-  
123 in the UL44 gene.

4. A method of claim 2, wherein said comprises an insertion in the UL44 gene which  
15 codes for glycoprotein C.

5. A method of claim 1, wherein the parental strain of said virus is KOS.

6. A method of claim 1, wherein said virus is gC-39.

7. A method of claim 1, wherein said virus is impaired in its ability to infect, or attach  
to the surface of, cells as compared to the wild-type parental strain.

8. A method of claim 1, wherein said virus is impaired in its ability to infect neuronal  
25 cells as compared to the wild-type parental strain.

9. A method of claim 1, wherein said cancer is an adenocarcinoma.

**10.** A kit comprising a mutant human herpes simplex virus which is oncolytic to cells in a neoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C and a chemotherapeutic agent.

5

**11.** A pharmaceutical composition comprising a mutant human herpes simplex virus wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide coded for by the UL 44 gene, and a sterile physiologically balanced solution.

10

**12.** A pharmaceutical composition as described in claim 11 wherein said mutant human herpes simplex virus is present at  $10^4$ –  $10^{12}$  pfu.

**13.** A pharmaceutical composition as described in claim 12 further comprising a chemotherapeutic agent.

15